ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 257.76

Change

+3.02 (+1.19)%

Market Cap

USD 3.92B

Volume

0.93M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 115.69B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 53.25B
ARGX argenx NV ADR

N/A

USD 34.54B
ONC BeiGene, Ltd.

N/A

USD 27.70B
RPRX Royalty Pharma Plc

N/A

USD 18.35B
INSM Insmed Inc

N/A

USD 17.98B
SMMT Summit Therapeutics PLC

N/A

USD 13.53B
INCY Incyte Corporation

N/A

USD 13.31B
EXEL Exelixis Inc

N/A

USD 11.39B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 10.98B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 6.36 % 0.00 %

N/A

USD 4.76M
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 5.15 % 0.00 %

N/A

USD 8.06M
GN0M:XETRA Global X Genomics & Biote.. 4.69 % 0.00 %

N/A

USD 7.05M
GNOM:SW 4.69 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
CURE:AU Global X S&P Biotech ETF 2.60 % 0.00 %

N/A

USD 0.04B
DOCG:LSE L&G Healthcare Breakthrou.. 2.54 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 2.54 % 0.00 %

N/A

USD 0.06B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.46 % 0.00 %

N/A

USD 0.04B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.27 % 0.00 %

N/A

USD 0.05B
DOCT:SW L&G Healthcare Breakthrou.. 2.22 % 0.00 %

N/A

USD 0.06B
JNDQ:AU Betashares Nasdaq Next Ge.. 2.14 % 0.00 %

N/A

N/A
FXH First Trust Health Care A.. 2.11 % 0.63 %

N/A

USD 0.90B
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA 0.87 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.33B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.04B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 5.11B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.54B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.04B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.04B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.21B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.60B
QQQN 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 8.18M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 8.18M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.66% 80% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.66% 80% B- 88% B+
Trailing 12 Months  
Capital Gain 27.67% 79% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.67% 79% B- 83% B
Trailing 5 Years  
Capital Gain 260.30% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 260.30% 92% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 16.57% 72% C 76% C+
Dividend Return 16.57% 72% C 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.99% 83% B 59% D-
Risk Adjusted Return 53.47% 94% A 81% B-
Market Capitalization 3.92B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 309.37 0% 1%
Price/Free Cash Flow Ratio -81.96 99% 97%
Management Effectiveness  
Return on Equity -1,500.66% 5% 2%
Return on Invested Capital -34.83% 70% 28%
Return on Assets -3.05% 94% 45%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.